Search results for: “cat”

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016) Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG)…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016) Updates since publication: No updates on dosing recommendations since publication. Tables provided in the main manuscript of the guideline: Table 1. Assignment of likely CYP2C19 phenotype based on genotypes Table 2. Dosing recommendations for voriconazole based on CYP2C19…

CPIC’s therapeutic recommendations are based on weighing the evidence from a combination of preclinical functional and clinical data, as well as on some existing disease-specific consensus guidelines. Some of the factors that are taken into account in evaluating the evidence supporting therapeutic recommendations include: in vivo pharmacokinetic and pharmacodynamic data, in vitro enzyme activity of…

CPIC assigns levels to the evidence linking genotype to phenotype.  The literature-based evidence summarized in each guideline’s supplement is graded¹ on a scale of high, moderate and weak, defined as follows: High: Evidence includes consistent results from well-designed, well-conducted studies. Moderate: Evidence is sufficient to determine effects, but the strength of the evidence is limited by…

ClinPGx 2024 Meeting Registration open In collaboration with CPIC, PharmGKB, PharmCAT and PharmVar, the Penn Institute for Biomedical Informatics will be hosting the ClinPGx 2024: Knowledge, Implementation, Education meeting on June 20th and 21st, 2024 in Philadelphia, PA. This meeting will provide educational content to cover all aspects of PGx implementation. Participants are invited to submit…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020) Updates since publication: No updates on dosing recommendations since publication. Tables and figure provided in the main manuscript of the guideline: Table 1. Assignment of likely HLA-B phenotypes based on genotypes Table 2. Assignment of…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022) Updates since publication: None Tables in the main manuscript of the guideline: Table 1. Assignment of Predicted CYP2C19 Phenotype Based on Genotype Table 2. Antiplatelet therapy recommendations based on CYP2C19 phenotype when considering clopidogrel for cardiovascular…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update (December 2016) Updates since publication: No updates on dosing recommendations since this publication. Figures provided in the main manuscript of the guideline: Figure 1. Schematic representation of warfarin metabolism and its mechanism of action. Figure 2. Dosing recommendations for…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015) Updates since publication: No updates on dosing recommendations since publication. Tables provided in the main manuscript of the guideline: Table 1. Assignment of likely metabolism phenotypes based on CYP3A5 diplotypes Table 2. Dosing recommendations for tacrolimus based…

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014) Updates since publication: No updates on dosing recommendations since publication. Tables provided in the main manuscript of the guideline: Table 1 Assignment of probable IFNL3 phenotypes based on genotypes Table 2 Recommendations for use of…